Posted on 05/28/16 by defeatHIV
Genome editing in hematopoietic stem and progenitor cells (HSPCs) is a promising novel technology for the treatment of many human diseases. Here, we evaluated whether the disruption of the C-C chemokine receptor 5 (CCR5) locus in pigtailed macaque HSPCs by zinc finger nucleases (ZFNs) was feasible. We show that macaque-specific CCR5 ZFNs efficiently induce CCR5 […]
Read more
Posted on 03/01/16 by defeatHIV
HIV curative strategies currently under development aim to eradicate latent provirus, or prevent viral replication, progression to AIDS, and transmission. The impact of implementing curative programs on HIV epidemics has not been considered. We developed a mathematical model of heterosexual HIV transmission to evaluate the independent and synergistic impact of ART, HIV prevention interventions and […]
Read more
Posted on 02/15/16 by defeatHIV
Incurable chronic viral infections are a major cause of morbidity and mortality worldwide. One potential approach to cure persistent viral infections is via the use of targeted endonucleases. Nevertheless, a potential concern for endonuclease-based antiviral therapies is the emergence of treatment resistance. Here we detect for the first time an endonuclease-resistant infectious virus that is […]
Read more
Posted on 01/19/16 by defeatHIV
The ability to continue combination antiretroviral therapy (cART) in human immunodeficiency virus (HIV)-infected patients undergoing hematopoietic cell transplantation (HCT) for treatment of hematologic malignancies is likely a critical factor in preventing the establishment of an HIV reservoir in transplanted stem cells. Thus, we studied the feasibility of continued antiretroviral therapy in our HIV-infected patients undergoing […]
Read more
Posted on 02/21/14 by defeatHIV
The cure of a human immunodeficiency virus (HIV)-1-infected patient following allogeneic transplantation from a CCR5-null donor and potential cure of two patients transplanted with CCR5 wild-type hematopoietic stem cells (HSC) have provided renewed optimism that a potential alternative to conventional antiretroviral therapy (ART) is forthcoming. While allogeneic grafts have thus far suggested complete eradication of […]
Read more
Posted on 07/27/13 by defeatHIV
The ‘Berlin Patient’, who maintains suppressed levels of HIV viremia in the absence of antiretroviral therapy, continues to be a standard bearer in HIV eradication research. However, the unique circumstances surrounding his functional cure are not applicable to most HIV(+) patients. To achieve a functional or sterilizing cure in a greater number of infected individuals […]
Read more
Posted on 07/13/12 by defeatHIV
Extended Survival of Glioblastoma Patients After Chemoprotective HSC Gene Therapy Science Translational Medicine May 2012 Jennifer E. Adair, Brian C. Beard, Grant D. Trobridge, Tobias Neff, Jason K. Rockhill, Daniel L. Silbergeld, Maciej M. Mrugala, and Hans-Peter Kiem MRI of the brain (subject one). Axial T1 post gadolinium sequences at the level of midbrain. A. […]
Read more
Posted on 03/14/12 by defeatHIV
Hematopoietic-Stem-Cell-Based Gene Therapy for HIV Disease Cell Stem Cell Feb 2012 Hans-Peter Kiem, Keith R. Jerome, Steven G. Deeks, Joseph M. McCune Investigators from defeatHIV and the Delaney AIDS Research Enterprise (DARE), two of the three NIAID Martin Delaney Collaboratories, partner to review HSC-based gene therapy strategies for HIV disease – demonstrating how scientists in […]
Read more